ALPHANATE ordering, coding, and billing

Order ALPHANATE from these authorized distributors

ASD Healthcare

BDI Pharma, Inc.


Cardinal Health Specialty Pharmaceutical Distribution

FFF Enterprises

McKesson Plasma and Biologics, LLC

National Hospital Specialties

Prodigy Health Supplier

For more information, call Grifols Customer Service at 888-GRIFOLS (888-474-3657).

Coding and billing

ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) coding and billing chart.

Coding System Code Description
Product CPT® and/or HCPCS J7186 Injection antihemophilic factor VIII/von Willebrand factor complex (human), per factor VIII IU
Administration CPT 96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
Administration CPT 96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour
ICD-9-CM 286.0 Congenital factor VIII disorder
ICD-9-CM 286.4 von Willebrand's disease
ICD-10-CM D66.0 Hereditary factor VIII deficiency
ICD-10-CM D68.0 von Willebrand's disease
Product NDC 68516-4601-1 or 68516-4611-1 250 IU (5 mL diluent)
Product NDC 68516-4602-1 or 68516-4612-1 500 IU (5 mL diluent)
Product NDC 68516-4603-2 or 68516-4613-2 1000 IU (10 mL diluent)
Product NDC 68516-4604-2 or 68516-4614-2 1500 IU (10 mL diluent)
Product NDC 68516-4609-2 or 68516-4615-2 2000 IU (10 mL diluent)


ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) is indicated for:

  • Control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with factor VIII (FVIII) deficiency due to hemophilia A
  • Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (type 3) undergoing major surgery
Important Safety Information

ALPHANATE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

Anaphylaxis and severe hypersensitivity reactions are possible with ALPHANATE. Discontinue use of ALPHANATE if hypersensitivity symptoms occur, and initiate appropriate treatment.

Development of procoagulant activity-neutralizing antibodies (inhibitors) has been detected in patients receiving FVIII-containing products. Carefully monitor patients treated with AHF products for the development of FVIII inhibitors by appropriate clinical observations and laboratory tests.

Thromboembolic events have been reported with AHF/VWF complex (human) in VWD patients, especially in the setting of known risk factors.

Intravascular hemolysis may occur with infusion of large doses of AHF/VWF complex (human).

Rapid administration of a FVIII concentrate may result in vasomotor reactions.

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE.

The most frequent adverse drug reactions reported with ALPHANATE in >1% of infusions were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash, and chills.

Please see full Prescribing Information for ALPHANATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1.800.FDA.1088.